Talazoparib in Combination With Enzalutamide for Prostate Cancer - FDA Oncology

Talazoparib in Combination With Enzalutamide for Prostate Cancer – FDA Oncology

FDA Oncology posted on X/Twitter:

“FDA Approval Summary: Talazoparib in Combination With Enzalutamide for Treatment of Patients With Homologous Recombination Repair Gene-Mutated Metastatic Castration-Resistant Prostate Cancer – Journal of Clinical Oncology. 1st author Brian Heiss, last author Daniel Suzman.“

Image

View additional information.
Source: FDA Oncology/X

Brian Heiss cancer Daniel Suzman Enzalutamide FDA Approval Summary FDA Oncology Journal of Clinical Oncology OncoDaily Oncology Talazoparib